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Background: The purpose of this study is to report prolonged survival in patients with metastatic pancreatic ductal
adenocarcinoma (PDAC) managed by chemotherapy and surgery.
Methods: Between January 2009 and August 2013, 284 patients with metastatic PDAC were managed in our
oncologic department. Among them, three (1%) with a single metastasis (liver in two cases and interaorticaval in
one case) underwent one- or two-stage surgical resection of the metastasis and the main tumor. Perioperative data
were recorded retrospectively, including disease-free and overall survival.
Results: The three patients had chemotherapy (FOLFOX or FOLFIRINOX regimen) with objective response or stable
disease prior to surgery. Median time between chemotherapy and surgery was 9 (8 to 15) months. Resection
consisted in pancreaticoduodenectomy in the three cases. None of the patients had grade III/IV postoperative
complications, and median hospital stay was 12 (12 to 22) days. All the patients had postoperative chemotherapy.
Only one patient experienced recurrence 11 months after surgery and died after 32.5 months. The two other
patients were alive with no recurrence 26.3 and 24.7 months after initial treatment.
Conclusion: Radical resection of PDAC with single distant metastases can offer prolonged survival with low
morbidity after accurate selection by neoadjuvant chemotherapy.
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer-related deaths in the United
States and the sixth in Europe and Japan [1]. Surgery re-
mains the only chance of cure and should be performed
when involvement is limited to the pancreatic gland. In
cases of advanced disease, such as major vascular in-
volvement, peritoneal carcinomatosis or distant metasta-
sis, palliative treatment is mandatory because surgery is
of no benefit while incurring a high risk of complications
and patient discomfort [2]. Despite aggressive surgical
therapy, only 10 to 15% of patients are eligible for cura-
tive resection, which provides a long term survival rarely
exceeding 20% at 5 years [3]. The high rate of recurrence* Correspondence: ebuc@chu-clermontferrand.fr
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unless otherwise stated.after curative resection suggests frequent occult disease or
micrometastasis at the time of surgery [4]. For this reason,
adjuvant gemcitabine-based chemotherapy has become a
standard treatment following resection of PDAC, although
the FOLFIRINOX regimen has been recently approved as
a new alternative in selected patients [5].
Surgical resection of PDAC with synchronous distant
metastases is not mandatory since median survival time
is equivalent to that of chemotherapy alone [6]. How-
ever, several publications have reported successful resec-
tion of PDAC with distant metastases and long-term
survival [7-10]. In these observations, neoadjuvant sys-
temic chemotherapy or chemoradiation was adminis-
tered initially because the disease was considered to be
palliative. However, objective response based on imagery
and blood markers suggested that occult disease had
disappeared, so we decided to perform laparotomy and
resection.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Oncologic data at diagnosis of the 689 patients
Entire cohort 689




Distant lymph nodes 42 (14.8)
Others 36 (12.7)
Locally advanced (%) 261 (37.9)
Resectable (%) 144 (20.9)
apatients could have several metastatic sites.
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and distant metastases who underwent pancreaticoduode-
nectomy (PD) following objective response to neoadjuvant
chemotherapy.
Methods
Between January 2009 and August 2013, 689 patients were
investigated in our unit for PDAC. Management of PDAC
in our tertiary center is consistent with international rec-
ommendations [11].
Pre-therapeutic assessment
All patients were first assessed using contrast-enhanced
computed tomography. In the event of distant metasta-
ses or locally advanced disease (involvement of the su-
perior mesenteric artery or the celiac axis), percutaneous
or endoscopic ultrasound guided biopsy was performed
for histological diagnosis, and chemotherapy was admin-
istered based on a multidisciplinary review. Endoscopic or
percutaneous stenting was mandatory when total serum
bilirubin was >1.5 mg/dL to allow chemotherapy [12]. For
resectable patients, preoperative biopsy was not per-
formed routinely, and stenting with a short metallic cover-
able stent was performed when we estimated that total
serum bilirubin would be higher than 15 mg/dL at the
time of laparotomy [13].
Therapeutic strategy
All patients were discussed in our oncological multidis-
ciplinary review board. Details of the therapeutic options
were given to the patients, and treatment was started
after informed consent. Patients with resectable disease
at preoperative evaluation were considered for resection.
After abdominal exploration and fresh frozen section,
patients with para-aortic lymph node involvement (consid-
ered as distant metastases), peritoneal dissemination, liver
metastasis or arterial encasement (without prior chemo-
therapy) underwent a palliative procedure. All other pa-
tients were considered eligible for resection. For tumors
located in the head of the pancreas, the standard proced-
ure was PD with posterior first approach of the superior
mesenteric artery (SMA). For tumors located on the left
of the splenoportal confluence, the standard procedure
was distal pancreatectomy with splenectomy and lymph
node dissection along the left aspect of the celiac axis and
the superior mesenteric artery. Extended lymphadenec-
tomy was not performed routinely. Postoperatively, all the
patients received adjuvant gemcitabine-based chemother-
apy except in case of poor general condition. Patients with
locally advanced disease underwent initial chemotherapy
based on a multidisciplinary review and, in the event of
objective response, surgical exploration and resection
when involvement was still limited to the pancreatic
gland. Patients with metastatic disease diagnosed eitherpreoperatively or intra-operatively were considered suit-
able for definitive palliative chemotherapy.
Oncologic follow-up
All patients were assessed by physical examination, tumor
biomarker CA19-9 and computed tomography (CT) scan.
Patients with resectable disease were screened every
3 months for the first year and every 6 months there-
after. Recurrences were treated with gemcitabine-based
or FOLFIRINOX regimen based on a multidisciplinary re-
view. Patients with advanced disease were assessed after
first-line chemotherapy. In cases of objective response,
surgical resection was reconsidered. Patients with meta-
static disease were assessed after each line of chemother-
apy, and the following treatment was decided on after a
multidisciplinary review.
Results
Two hundred eighty-four patients (41.2%) had metastatic
disease (199 to the liver, 90 to the peritoneum, 60 to the
lung, 42 to the lymph nodes and 36 elsewhere), 261
(37.9%) had locally advanced disease, and 144 (20.9%)
were resectable (Table 1). Of the patients with metastatic
disease, 3 (1.0%) underwent resection of both the primary
tumor and metastases. Clinical and perioperative data are
summarized in Table 2.
Patient number 1
Patient number 1 was a 65-year-old male with no previous
history. Clinical symptoms were abdominal pain and jaun-
dice. Initial CT scan showed locally advanced PDAC
(44 mm) with extension to the SMA and SMV (Figure 1).
PET scan confirmed the absence of detectable liver metasta-
ses. Twelve cycles of neoadjuvant chemotherapy (FOLFOX
regimen) were administered. Tumor biomarker CA19-9
returned to normal range at the end of the treatment (2876
to 34.8 UI/L). CT scan evaluation showed stable disease
with no distant metastases. Surgery was decided on be-
cause of the initial good response to chemotherapy and
stable disease after a period of 9 months. At laparotomy,
Table 2 Clinical data for the three patients
Patient 1 Patient 2 Patient 3
Age 65 53.5 60
Sex M F F
BMI 25.7 19.5 21.8
Initial CA19-9 2876 200 34.1
Initial treatment CT Surgery Surgery
Site of metastases Liver Interaortocaval nodes Liver
Number of metastases Single Single Single
Time between first line CT scan and resection 9 months 8 months 15 months
Preoperative CA19-9 34.8 5 17
Type of resection PD with resection of SMA and PV PD with resection of PV PD with resection of SMV
Underlying IPMN No No No
pTNM stage T4 N0 M1 T3 N0 M1 T3 N1 M1
Retroportal margin >1 mm >1 mm >1 mm
Posterior margin >1 mm >1 mm <1 mm
Anterior margin >1 mm >1 mm >1 mm
Follow-up (months) 32.5 26.3 24.7
Recurrence Yes No No
Disease-free progression (months) 11 / /
CT, systemic chemotherapy; BMI, body mass index; IPMN, intraductal papillary mucinous neoplasm; PD, pancreaticoduodenectomy; PV, portal vein SMA, superior
mesenteric artery; SMV, superior mesenteric vein.
Figure 1 Computed tomography (CT) scan of patient number 1 showing a tumor of the head of the pancreas (T) with infiltration of
both the superior mesenteric vein (SMV) (white arrow) and the superior mesenteric artery (SMA) (yellow arrow). (A) Axial view;
(B) frontal view; (C) sagittal view.
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resected with intraoperative frozen section that exhibited
no neoplastic cells. PD with superior mesenteric artery
(SMA) and portal vein (PV) en bloc resection was then
performed. The SMA was reconstructed by termino-
terminal end-to-end anastomosis. The PV was recon-
structed by end-to-end anastomosis between the superior
mesenteric vein (SMV) and the PV, and the splenic vein
was re-implanted in the inferior mesenteric vein. The
conclusion of the final pathologist’s report was PDAC with
portal vein invasion but no arterial invasion and without
lymph node involvement. The lesion of segment I was
metastatic with large areas of necrosis. The tumor was
classified as pT3 N0 M1. The postoperative course was
uneventful and the patient was discharged on post-
operative day 22. Six cycles of adjuvant chemotherapy
(half-dose of GEMOX regimen because of severe throm-
bopenia) were administered postoperatively (Table 3).
Patient number 2
Patient number 2 was a 53.5-year-old female. Clinical
symptoms were abdominal pain. Preoperative imaging
showed a 65-mm lesion of the head of the pancreas with
both portal vein and mesenteric arterial involvement.
Despite this, she had undergone surgical exploration in a
previous center, which confirmed neoplastic portal
thrombosis and SMA invasion (Figure 2). Interaortocaval
lymph node procurement with intraoperative frozen sec-
tion showed metastatic lymph nodes with capsular dis-
ruption. Resection was abandoned and a double bypass
(hepaticojejunostomy and gastroenterostomy) was per-
formed. The patient underwent systemic chemotherapy
(six cycles of FOLFIRINOX regimen followed by two cy-
cles of FOLFIRI) after the initial palliative procedure. At
the end of chemotherapy, a CT scan showed a dramatic
decrease in the size of the tumor (63 mm to 32 mm),
loss of the SMA encasement and partial recanalization of
the portal vein. Tumor biomarker CA19-9 had returned
to normal range (200 to 5 UI/L). The patient had a weight
gain of 4 kilograms and was in good general condition.
Resection was decided on because of objective response
and stable disease after a period of 8 months. PD with por-
tal vein en bloc resection was performed. The conclusion
of the final pathologist’s report was PDAC with portal vein
invasion without lymph node involvement. Posterior re-
section margin was <1 mm. The tumor was classified as
pT3 N0 M0. The postoperative course was uneventful,Table 3 Adjuvant chemotherapy regimen for the three patien
Patient number 1
First-line (adjuvant) chemotherapy GEMOX (6 cycles)
Second-line chemotherapy FOLFOX (8 cycles)
Third-line chemotherapy FOLFIRI (6 cycles)and the patient was discharged on postoperative day 12.
Six cycles of adjuvant FOLFOX chemotherapy were
administered postoperatively (Table 3).
Patient number 3
Patient number 3 was a 60-year-old female. Clinical
symptoms were abdominal pain. Preoperative imaging
showed a 38-mm lesion of the head of the pancreas with
no vascular invasion and no distant metastases (Figure 3).
She had undergone surgical exploration in a previous
center. At laparotomy, a suspect lesion in segment III
was resected. Intraoperative frozen section showed evi-
dence of liver metastasis from PDAC. Resection was aban-
doned and gastroenterostomy was performed. The patient
underwent postoperative systemic chemotherapy (12 cycles
of FOLFIRINOX followed by 7 cycles of gemcitabine). At
the end of chemotherapy, a CT scan showed no progres-
sion of the disease, and tumor biomarker CA19-9 was
within the normal range (34.1 UI/L prior to chemotherapy
and 17 UI/L after the two lines of chemotherapy). The
patient was in good general condition. Resection was
decided on because of stable disease after a period of
14 months. PD with SMV en bloc resection was per-
formed because of suspected adhesions to the SMV. The
conclusion of the final pathologist’s report was PDAC with-
out SMV involvement and R0 resection margins. There
was no lymph node metastasis. Postoperative course was
uneventful, and the patient was discharged on postoperative
day 12. Eight cycles of adjuvant gemcitabine chemo-
therapy were administered postoperatively (Table 3).
Characteristics of metastases
Metastases were single and hepatic in two cases (patients
number 1 and number 3) and interaorticaval in the other
(patient number 2). For patients number 2 and number 3,
metastases had been resected at the time of primary
surgery whereas the single metastasis of patient number 1
was incidentally discovered and resected concomitantly
with PD. Liver metastases were <1 cm in the two patients
concerned.
Oncologic follow-up
Median follow-up was 26.3 months (range, 24.7 to
32.5 months). Patients number 2 and number 3 did not
experience recurrence until the last follow-up (26.3 and
24.7 months respectively). Patient number 1 had a huge
increase in CA19-9 11 months after surgery with nots
Patient number 2 Patient number 3
FOLFOX (6 cycles) GEMZAR (8 cycles)
/ /
/ /
Figure 2 Computed tomography (CT) scan of patient number 2 before the initial palliative bypass procedure (A) showing a huge
tumor of the head of the pancreas (T) with tumoral infiltration of both superior mesenteric vein (SMV) (white arrow) and superior
mesenteric artery (SMA) (yellow arrow). Following six cycles of FOLFIRINOX chemotherapy and bypass procedure, the CT scan showed
regression of the infiltration of the SMA with no detectable metastases (B).
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less, he received six cycles of chemotherapy at half-dose
because of thrombopenia (Table 3). A control CT scan
showed four liver and one lung metastases. The patient
received eight cycles of FOLFOX regimen followed by
six cycles of FOLFIRI regimen. He died 2 years after sur-
gery (32 months after the beginning of the disease).
Discussion
PDAC with synchronous distant metastases has a very
poor prognosis and in cohort studies median survival
rarely exceeds 6 months [14-16]. New regimens of chemo-
therapy and radiotherapy has improved the prognosis of
metastatic and/or locally advanced PDAC [17,18], but the
benefit of surgery in such cases is still a matter of debate.Figure 3 Computed tomography (CT) scan of patient number 3 befor
of the pancreas (T) with lack of invasion of superior mesenteric vein (
arrow) (A) but unrecognized subcapsular liver metastases (white arroHowever, there is robust evidence that some patients with
locally advanced or metastatic disease can be cured fol-
lowing aggressive therapy. In the study of Adham and co-
workers concerning prolonged survival after resection of
PDAC, six patients had advanced disease and one had
metastatic disease [19]. Bachellier and coworkers showed
that initially advanced disease could be down staged by
neoadjuvant chemotherapy, and that in such cases, resec-
tion offered a significant prolonged survival, as in patients
with initially resectable PDAC [20]. In contrast, Gleisner
and coworkers in 2007 reported a series of patients with
concomitant resection of pancreatic cancer and liver me-
tastasis [6]. In their series, 17 patients had PDAC, most of
them with a single liver metastasis. The authors concluded
that there was no benefit to resection of liver metastasese initial palliative bypass procedure showing a tumor of the head
SMV) (white arrow) and superior mesenteric artery (SMA) (yellow
w) (B).
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higher in resected patients (6.7% versus 0%). Finally, it is
likely that some patients with metastatic and/or locally
advanced PDAC have good molecular behavior and can
benefit from aggressive resection. However, the ability to
select such patients is currently not possible with standard
molecular biomarkers. Furthermore, standard imaging still
fails to detect millimetric metastasis that could improve
preoperative staging and thus avoid unnecessary resec-
tions. In this setting, preoperative chemotherapy acts as a
‘test-of-time’ and can help to select patients with less ag-
gressive PDAC that could benefit from radical surgery,
even in case of limited metastatic disease.
Consequently, resection of metastatic PDAC remains
challenging and raises three important questions. First, do
all types of distant metastases (for example, liver, nodal,
and peritoneal) have the same prognosis? PDAC with dis-
tant metastases is usually estimated as definitively nonre-
sectable and thus palliative chemotherapy is administered.
The results of series of metastatic PDAC have shown such
a poor prognosis that the impact of the type of metastasis
has been rarely investigated [6]. The AJCC-UICC staging
system attributes the item ‘M’ for metastatic disease, but
does not take into account the location of the metastases.
This problem is the same with the item ‘N’, for which it
has been shown that prognosis differs according to the
type of lymph node metastases (peripancreatic or mesen-
teric) [21]. Given that distant metastases have a very poor
prognosis, the metastatic site has little impact on thera-
peutic management. Distant metastases in PDAC are
most of the time visceral (liver, lung) or nodal (interaorti-
caval) [8]. However, despite no survival benefit of extended
lymphadenectomy in PDAC [22], metastatic interaortoca-
val lymph nodes seem to have a better prognosis than me-
tastases in other organs such as the liver and peritoneum
[23,24]. Similarly, local recurrence after initial resection
seems to have a better prognosis than metastatic recur-
rence, and can be managed by surgery with survival benefit
in selected patients [25]. Thus, in the event of objective re-
sponse to chemotherapy, the type of distant metastases
should be considered, as in our patient number 2. In such
cases, PD with systematic en bloc interaorticaval lymphad-
enectomy can be proposed since interaorticaval lymphade-
nectomy does not increase postoperative morbidity [26].
Second, is the number of metastases important? In pa-
tients number 1 and number 3 in our series, laparotomy
disclosed single liver metastases undetected by preopera-
tive imaging. Prognosis of PDAC with single liver metas-
tases is better than with multiple liver metastases, [27]
and a meta-analysis has shown that resection of PDAC
with single liver metastases was comparable to resection
of PDAC with no evidence of liver metastases [28]. As in
our study, documented reports of prolonged survival
after resection of liver metastases from PDAC involvedsingle and small metastases, incidentally discovered at
laparotomy [6,7,19]. PD may sometimes be performed
although there are concomitant single liver metastases
that were undetectable because of limited exploration of
the whole liver. This is consistent with the rapid time of
liver recurrence in PDAC after PD [6,27,29]. Given that
liver metastases have better prognosis than metastases in
other sites (locoregional or peritoneal) [30], single and small
liver metastases may indicate a low metastatic volume, as
in metastatic colorectal cancer [31] and do not have to be
considered as definitely palliative, especially in the event
of objective response to chemotherapy.
Third, can we manage liver metastases surgically with-
out previous neoadjuvant therapy? In comparison to colo-
rectal liver metastases (CRLM), concomitant resection of
single liver metastases with PDAC has two drawbacks: ad-
juvant chemotherapy in PDAC is not as efficient as in
CRLM, and PD is a major procedure with a high risk of
morbidity - in particular pancreatic fistula - that increases
the risk of recurrence and reduces the likelihood of receiv-
ing adjuvant chemotherapy [32]. However, as indicated
above, liver metastases in PDAC may not necessarily be a
contraindication to surgery. Laurent and coworkers dem-
onstrated that non-colorectal metachronous liver metasta-
ses could justify resection leading to increased survival
[33]. In contrast, Gleisner and coworkers in 2007 found
no benefit of concomitant resection of PDAC with single
liver metastases compared to a palliative procedure [6].
Likewise, Takada and coworkers showed no improve-
ment of survival despite aggressive surgery of PDAC with
multiple liver metastases [29]. However, in these two latter
studies liver resection of synchronous metastases was per-
formed without neoadjuvant chemotherapy, and recurrence
occurred less than 4 months after surgery, suggesting a
non-controlled disease [6]. As in CRLM, management of
liver metastases needs a ‘test-of-time’, to ensure the con-
trol of the disease [34]. In this setting, the FOLFIRINOX
regimen showed very promising results compared to the
low rate of objective response of a gemcitabine-based regi-
men [17,35-37]. Additionally, the cost-effectiveness of
neoadjuvant treatment seems to be superior to that of a
surgery-first approach [38]. Thus, simultaneous resection
of PDAC with single liver metastasis - and by extension all
types of distant metastases - should be considered in the
setting of neoadjuvant chemotherapy, first to assess the re-
sponse to chemotherapy and second to assess the aggres-
siveness of the disease. In the event of objective response,
surgical resection can be considered in selected patients
with low-volume metastatic liver disease and very good
general health status.
Conclusions
Our short series of three observations shows that R0
resection of PDAC with single distant metastases can
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chemotherapy. Only patient number 1 experienced recur-
rence, but this patient had a T4 tumor with a high risk of
local recurrence, and subsequent development of liver
metastases that occurred far from the initial site of recur-
rence. The high rate of recurrence of PDAC raises the
question of selecting good responders before resection of
PDAC on the basis of systematic neoadjuvant chemo-
therapy in order to improve long-term survival.
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